What experts from around the world say...

“…when a patient has already resistance to a second-generation tyrosine kinase inhibitor, what do you do next? …it is a complicated scenario, and it is one that emphasizes the need for additional treatment options.”
Jorge Cortes, MD. Georgia Cancer Center, USA

“…the tolerability issues of current TKIs for many patients highlight the need for new therapies.”
Eri Matsuki, MD. Keio University Hospital, Tokyo, Japan

“Resistance will continue to compromise our ability to promote long-term survival for our patients with CML, highlighting the need for a new therapy.”
Carla Boquimpani, MD. Hospital Hemorio, Rio de Janeiro, Brazil

“…from a clinical perspective, this approach of cycling through these [ATP-competitive] TKIs is not ideal, since resistance mutations in the ATP-binding site may render other TKIs ineffective, manifesting as multidrug resistance and impeding the potential to overcome resistance.”
Jorge Cortes, MD. Georgia Cancer Center, USA

“We, as oncologists, tend to rely on the big-time toxicities, and say, well, minor toxicities, please tolerate it. But, please understand, this is chronic treatment given over a long period of time, and quality of life of the patient is critical.”
Moshe Talpaz, MD. University of Michigan, USA

“Dose adjustment, particularly a dose increase of a tyrosine kinase inhibitor, has sometimes been used for patients who are developing suboptimal response or a resistance to therapy. However, in some studies, there has been compared that strategy versus changing, and changing tends to be better.”
Jorge Cortes, MD. Georgia Cancer Center, USA